Literature DB >> 18597639

Transdermal lovastatin enhances fracture repair in rats.

Gloria E Gutierrez1, James R Edwards, Ian R Garrett, Jeffry S Nyman, Brandon McCluskey, Gianni Rossini, Alda Flores, Daria B Neidre, Gregory R Mundy.   

Abstract

Statins have been shown to stimulate BMP2 transcription and bone formation. This raises the possibility that they could be useful for enhancing rates of fracture repair. Observational studies in patients treated with oral statins for lipid-lowering have been controversial. The likely reason for their inconsistent effects is that the statin concentration reaching the periphery was too low after oral administration to produce a reproducible biologic effect. Thus, we examined the effects of lovastatin (LV) given transdermally in a well-described preclinical model of fracture repair. Effects on the healing fracture callus were assessed by biomechanical strength, radiographs, and quantitative morphology. LV was administered transdermally (TD) for 5 days after fracture in several doses (0.1-5 mg/kg/d) and compared with vehicle-treated control rats and rats treated with LV by oral gavage (PO) at 5-25 mg/kg/d for 5 days from the day of fracture. Radiological evaluation of bones treated with TD LV showed enhanced fracture repair at 2 and 6 wk. BMD in the callus area at 6 wk was also increased in the TD group compared with vehicle-treated controls (p < 0.05). The force required to break TD-treated bones (0.1 mg/kg/d for 5 days) was 42% greater than vehicle-treated controls (p < 0.02), and there was a 90% increase in stiffness (p < 0.01). PO LV at much higher doses (10 and 25 mg/kg/d) showed increased stiffness but no change in other biomechanical properties. By histological examination, a significant increase was also observed in the size of the callus, surrounding proliferating cell nuclear antigen-positive cells, and osteoblast and osteoclast number in TD-treated rats compared with controls at day 8 after fracture (n = 6). In summary, we found that TD LV in low doses accelerates fracture healing, whereas 10-fold the lipid-lowering dose was required to produce any effect when it was administered orally. These studies provide valuable information on the potential of statins and TD delivery as a new and effective therapeutic modality in fracture repair.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18597639      PMCID: PMC2685484          DOI: 10.1359/jbmr.080603

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  41 in total

Review 1.  Statins and bone formation.

Authors:  I R Garrett; G Gutierrez; G R Mundy
Journal:  Curr Pharm Des       Date:  2001-05       Impact factor: 3.116

2.  Expression and activation of the BMP-signaling components in human fracture nonunions.

Authors:  Peter Kloen; Steven B Doty; Eric Gordon; Iván F Rubel; Marie-José Goumans; David L Helfet
Journal:  J Bone Joint Surg Am       Date:  2002-11       Impact factor: 5.284

3.  Lovastatin stimulates human vascular smooth muscle cell expression of bone morphogenetic protein-2, a potent inhibitor of low-density lipoprotein-stimulated cell growth.

Authors:  Luca Emmanuele; Jana Ortmann; Tim Doerflinger; Tobias Traupe; Matthias Barton
Journal:  Biochem Biophys Res Commun       Date:  2003-02-28       Impact factor: 3.575

4.  Differential temporal expression of members of the transforming growth factor beta superfamily during murine fracture healing.

Authors:  Tae-Joon Cho; Louis C Gerstenfeld; Thomas A Einhorn
Journal:  J Bone Miner Res       Date:  2002-03       Impact factor: 6.741

5.  Simvastatin induces osteoblastic differentiation and inhibits adipocytic differentiation in mouse bone marrow stromal cells.

Authors:  Chunli Song; Zhaoqing Guo; Qingjun Ma; Zhongqiang Chen; Zhongjun Liu; Hongti Jia; Gengting Dang
Journal:  Biochem Biophys Res Commun       Date:  2003-08-29       Impact factor: 3.575

6.  BMP signaling components are expressed in human fracture callus.

Authors:  P Kloen; M Di Paola; O Borens; J Richmond; G Perino; D L Helfet; M J Goumans
Journal:  Bone       Date:  2003-09       Impact factor: 4.398

7.  A single percutaneous injection of recombinant human bone morphogenetic protein-2 accelerates fracture repair.

Authors:  Thomas A Einhorn; Robert J Majeska; Ahamed Mohaideen; Eric M Kagel; Mary L Bouxsein; Thomas J Turek; John M Wozney
Journal:  J Bone Joint Surg Am       Date:  2003-08       Impact factor: 5.284

8.  Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials.

Authors:  Douglas C Bauer; Greg R Mundy; Sophie A Jamal; Dennis M Black; Jane A Cauley; Kristine E Ensrud; Marjolein van der Klift; Huibert A P Pols
Journal:  Arch Intern Med       Date:  2004-01-26

9.  Statin stimulates bone morphogenetic protein-2, aggrecan, and type 2 collagen gene expression and proteoglycan synthesis in rat chondrocytes.

Authors:  Hiroshi Hatano; Akihiro Maruo; Mark E Bolander; Gobinda Sarkar
Journal:  J Orthop Sci       Date:  2003       Impact factor: 1.601

10.  Bone morphogenetic protein receptor signaling is necessary for normal murine postnatal bone formation.

Authors:  Ming Zhao; Stephen E Harris; Diane Horn; Zhaopo Geng; Riko Nishimura; Gregory R Mundy; Di Chen
Journal:  J Cell Biol       Date:  2002-06-10       Impact factor: 10.539

View more
  10 in total

1.  Germline deletion of AMP-activated protein kinase beta subunits reduces bone mass without altering osteoclast differentiation or function.

Authors:  Julian M W Quinn; Shanna Tam; Natalie A Sims; Hasnawati Saleh; Narelle E McGregor; Ingrid J Poulton; John W Scott; Matthew T Gillespie; Bruce E Kemp; B J W van Denderen
Journal:  FASEB J       Date:  2009-09-01       Impact factor: 5.191

2.  STATINS AND BONE HEALTH: A MINI REVIEW.

Authors:  Leslie R Morse; Jennifer Coker; Ricardo A Battaglino
Journal:  Actual osteol       Date:  2018 Jan-Apr

3.  Saturated fatty acids enhance osteoclast survival.

Authors:  So-Ra Oh; Ok-Joo Sul; Youn-Young Kim; Hye-Jin Kim; Rina Yu; Jae-Hee Suh; Hye-Seon Choi
Journal:  J Lipid Res       Date:  2010-05       Impact factor: 5.922

Review 4.  Anabolic agents and bone quality.

Authors:  Tarek Sibai; Elise F Morgan; Thomas A Einhorn
Journal:  Clin Orthop Relat Res       Date:  2011-08       Impact factor: 4.176

5.  Preoperative statins improve recovery of renal function but not by an anti-inflammatory effect: observational study in 69 elderly patients undergoing cardiac surgery.

Authors:  Pierangela Presta; Antonino S Rubino; Gaetano Lucisano; Giuseppe F Serraino; Daniela Foti; Elio Gulletta; Attilio Renzulli; Giorgio Fuiano
Journal:  Int Urol Nephrol       Date:  2011-04-20       Impact factor: 2.370

6.  Free Fatty Acids in Bone Pathophysiology of Rheumatic Diseases.

Authors:  Klaus W Frommer; Rebecca Hasseli; Andreas Schäffler; Uwe Lange; Stefan Rehart; Jürgen Steinmeyer; Markus Rickert; Kerstin Sarter; Mario M Zaiss; Carsten Culmsee; Goutham Ganjam; Susanne Michels; Ulf Müller-Ladner; Elena Neumann
Journal:  Front Immunol       Date:  2019-12-03       Impact factor: 7.561

7.  Influence of statins locally applied from orthopedic implants on osseous integration.

Authors:  Stephan Pauly; David A Back; Kathrin Kaeppler; Norbert P Haas; Gerhard Schmidmaier; Britt Wildemann
Journal:  BMC Musculoskelet Disord       Date:  2012-10-26       Impact factor: 2.362

8.  Local inhibition of 5-lipoxygenase enhances bone formation in a rat model.

Authors:  J A Cottrell; V Keshav; A Mitchell; J P O'Connor
Journal:  Bone Joint Res       Date:  2013-02-01       Impact factor: 5.853

Review 9.  Effects of Statins on Bone Mineral Density and Fracture Risk: A PRISMA-compliant Systematic Review and Meta-Analysis.

Authors:  Zongze Wang; Ying Li; Fengxin Zhou; Zhe Piao; Jian Hao
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

10.  Lansoprazole Upregulates Polyubiquitination of the TNF Receptor-Associated Factor 6 and Facilitates Runx2-mediated Osteoblastogenesis.

Authors:  Kenichi Mishima; Hiroshi Kitoh; Bisei Ohkawara; Tatsuya Okuno; Mikako Ito; Akio Masuda; Naoki Ishiguro; Kinji Ohno
Journal:  EBioMedicine       Date:  2015-11-17       Impact factor: 8.143

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.